Evidence map›Paper›PMID 36043988›Full record

ArticleFuture microbiology2022

Risk factors in people with mold infections that have spread to different parts of the body: a plain language summary.

Anita H Sung, Stephan Martin, Bryant Phan, Michael Benigno, Jennifer Stephens, Jalal A Aram

Open access · hybridAbstract readComment
PubMed Publisher
In one paragraph

Article in Future microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Invasive splenic mucormycosis due toFrontiers in oncology · 2023
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Anita H SungPfizer Inc, New York, NY, USA.
Stephan MartinOPEN Health, Bethesda, MD, USA.
Bryant PhanPfizer Inc, New York, NY, USA.
Michael BenignoPfizer Inc, New York, NY, USA.
Jennifer StephensOPEN Health, Bethesda, MD, USA.
Jalal A AramPfizer Inc, New York, NY, USA.
Pfizer (United States) · USOpen Health Systems Laboratory · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

WHAT IS THIS SUMMARY ABOUT?: This is a summary of a study originally published in WHAT WERE THE RESULTS?: The main risks in people with invasive aspergillosis (shortened to IA) and invasive mucormycosis (shortened to IM) were: ○diabetes (high blood sugar and associated conditions), ○lung disease (such as tuberculosis, chronic obstructive pulmonary disorder), ○blood-related cancers (such as leukemia, lymphoma), and ○solid organ transplant (removing an organ from one person and placing in another person). WHAT DO THE RESULTS OF THE STUDY MEAN?: People with the risks listed above may be more likely to get invasive mold infections. People with these risks should talk to their doctor about invasive mold infections. Being aware of these risks may help doctors to be aware of which people are at risk of invasive mold infections.

Indexed as

invasive aspergillosisinvasive mold infectioninvasive mucormycosislay summaryplain language summary

Identifiers

PMID36043988
OpenAlexW4293833994

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.